玻璃体腔注射阿柏西普治疗难治性色素上皮脱离伴或不伴视网膜下液继发于年龄相关性黄斑变性的结局
这项前瞻性非随机干预病例系列纳入40例既往接受至少3次贝伐珠单抗或雷珠单抗注射后仍持续存在血管化色素上皮脱离(PED)的新生血管性年龄相关性黄斑变性患者,给予阿柏西普3次初始负荷剂量后按需治疗48周。PED体积在第8周显著降低、第48周回升,视网膜下液体积和第48周中心亚区厚度显著降低,最佳矫正视力维持;实性型PED的改善较差。
要点
- 阿柏西普使难治性PED体积第8周显著降低,第48周回升且未达统计学显著。
- 视网膜下液体积第48周显著降低,中心亚区厚度显著降低,最佳矫正视力维持。
- 实性型PED在中心亚区厚度、最佳矫正视力及SRF和PED体积方面改善较差。
核心结论
- 玻璃体腔注射阿柏西普治疗难治性新生血管性年龄相关性黄斑变性在12个月内显著降低PED体积、视网膜下液体积和中心亚区厚度,最佳矫正视力维持。
- 实性型PED的改善程度低于空心型或混合型PED。
研究设计与样本
- 前瞻性、非随机、干预性病例系列,纳入40例既往接受至少3次玻璃体腔贝伐珠单抗或雷珠单抗注射后仍持续存在血管化PED的患者。
- 阿柏西普给药方案为3次初始负荷剂量每4周一次,随后按需再治疗每8周一次,持续48周。
- 根据光学相干断层扫描反射特性将PED分为实性型、空心型或混合型。
主要发现
- PED体积基线为0.43±0.55 mm,第8周显著降至0.23±0.32 mm(P=0.003),第48周升至0.36±0.41 mm(P=0.345)。
- 视网膜下液体积基线为0.52±0.64 mm,第48周显著降至0.24±0.43 mm(P=0.021)。
- 最佳矫正视力基线为20/75(47.5个字母),第48周变化+4.4个字母,无显著差异(P=0.125)。
- 中心亚区厚度基线为323.2±92.3 μm,第48周显著降至281.2±90.7 μm(P=0.001)。
- 实性型PED在中心亚区厚度、最佳矫正视力及SRF和PED体积方面改善较差,并出现新发视网膜内囊肿。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the outcomes of intravitreal aflibercept in refractory pigment epithelial detachment (PED) with or without subretinal fluid (SRF) in patients with neovascular age-related macular degeneration. METHODS: A prospective, nonrandomized, interventional case series involved 40 patients with persistent vascularized PED previously treated with at least 3 injections of intravitreal bevacizumab or ranibizumab. Intravitreal aflibercept was administered as 3 initial loading doses every 4 weeks, followed by pro re nata retreatment every 8 weeks over 48 weeks. Pigment epithelial detachment was classified into solid-, hollow-, or mixed-type according to the reflective properties visualized using optical coherence tomography. The mean changes in best-corrected visual acuity, central subfield thickness, and the volumes of SRF and PED were analyzed. RESULTS: The PED volume (baseline: 0.43 ± 0.55 mm) significantly reduced to 0.23 ± 0.32 mm at Week 8 (P = 0.003) and increased to 0.36 ± 0.41 mm at Week 48 (P = 0.345). The SRF volume (baseline: 0.52 ± 0.64 mm) significantly reduced to 0.24 ± 0.43 mm at Week 48 (P = 0.021). The mean baseline best-corrected visual acuity was 20/75 (47.5 letters); it showed no significant difference at Week 48 (+4.4 letters; P = 0.125). The baseline central subfield thickness was 323.2 ± 92.3 μm; it significantly reduced to 281.2 ± 90.7 μm at Week 48 (P = 0.001). In solid-type PEDs, there were poorer improvements in central subfield thickness, best-corrected visual acuity, and the volumes of the SRF and PED, with newly developed intraretinal cysts. CONCLUSION: Intravitreal aflibercept in treatment-resistant neovascular age-related macular degeneration led to significant reduction in PED and SRF volume, central subfield thickness, and best-corrected visual acuity preserved, over 12 months. However, solid-type PED showed less improvement than hollow- or mixed-type PED.
引用
- Kim K, Kim ES, Kim Y, et al. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina. 2019. PMID: 29160779. doi:10.1097/IAE.0000000000001947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。